U.S. pharmaceutical giant Pfizer submitted to regulators on Wednesday the documentation on phase 3 trials of its coronavirus vaccine, developed in partnership with German biotechnology company BioNTech.
Pfizer, however, states that it has not asked for emergency use clearance. Instead, its move was part of the continuous process of providing data to prove the vaccine’s effectiveness and safety. “This process has been ongoing since late in November,” said the company in a statement to the press.
Also in a statement, federal health watchdog Anvisa said safety, efficiency, and quality controls will only be completed with the full data — and only then clearance will become a possibility.
At this point, no company has requested authorization for emergency use in Brazil.
Support this coverage →In 2000, Formula 1 great Michael Schumacher had just racked up his 41st race win,…
Overall, the worldwide economic outlook has improved according to the Organization for Economic Co-operation and…
“This is f***ing corruption, it has to change,” protested an irate John Textor, owner of…
Eduardo Leite, governor of the southern Brazilian state of Rio Grande do Sul, on Wednesday…
Moody’s is the latest rating agency to improve its assessment of Brazil, bumping up the…
Other finalists include the Harvard Business Review, Fortune, Condé Nast, and the NFL